<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01710956</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-11-531</org_study_id>
    <nct_id>NCT01710956</nct_id>
  </id_info>
  <brief_title>Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase II Study of Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>5years after chemoradiotherapy</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Limited Disease Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1(with twice-daily TRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (with once-daily TRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy</intervention_name>
    <description>Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)</description>
    <arm_group_label>Arm 1(with twice-daily TRT)</arm_group_label>
    <arm_group_label>Arm 2 (with once-daily TRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically (if cannot be proven histologically, at least twice
             positive findings on fine needle aspiration or sputum cytology) confirmed SCLC

          -  Limited stage (Clinical stage I-IIIb, lesion limited to one side of thorax, e.g.
             Excluding T4 disease with malignant pleural effusion or N3 disease with contralateral
             hilum/supraclavicular lymph node invasion).

          -  Measurable or assessable lesion

          -  Age over 18 years old

          -  Performance status (ECOG scale): 0~2

          -  Adequate organ functions: ANC ≥ 1500/ul, PLT ≥ 100 x 103/u, Total Bilirubin ≤ 1.5
             mg/dl, Creatinine ≤ 1.5 mg/dl

          -  Inclusion of tumor within the limited radiation field without significant loss of
             pulmonary function (confirmed by radiation oncologist)

          -  Sexually active fertile men and women using a contraceptive method

          -  Patients should sign a written informed consest before study entry

        Exclusion Criteria:

          -  T4 disease with malignant pleural effusion; N3 disease with contralateral
             hilum/supraclavicular lymph node invasion

          -  Lesion with mixed small cell nonsmall cell feature (pathologically)

          -  prior chemotherapy or radiation therapy.

          -  Pericardial or pleural effusion on chest X-ray image regardless of cytological finding

          -  T4 disease with tumor invasion to great vessels, heart, trachea, or esophagus;
             Concerns about possible perforation by tumor necrosis

          -  Severe comorbidities such as cardiac disease with symptom, myocardiac infarction
             within 6 months, chronic obstructive pulmonary disease with FEV1 less than 1.0ℓ, or
             uncontrolled bronchospasm of unaffected lung

          -  With atelectasis that makes GTV unidentifiable

          -  Other primary malignancy (except in situ carcinoma of the cervix or adequately treated
             basal cell carcinoma of the skin or prior malignancy treated more than 3 years ago
             without recurrence)

          -  Uncontrolled psychiatric disorder, serious head injury, chronic alcoholism, drug
             addiction and central nervous system disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwan Ho Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kwan Ho Cho, M.D.</last_name>
    <phone>+82 31 920 1720</phone>
    <email>kwancho@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sung Ho Moon, M.D.</last_name>
    <phone>+82 31 920 1726</phone>
    <email>shmoon@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Canter, Korea</name>
      <address>
        <city>Ilsan-ro 323, Ilsandoung-gu, Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwan Ho Cho, M.D.</last_name>
      <phone>+82 31 920 1720</phone>
      <email>ncckrog@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sung Ho Moon, M.D.</last_name>
      <phone>+82 31 920 1726</phone>
      <email>ncckrog@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Sung Ho Moon, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Soo Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heung Tae Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Youn Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tak Yun, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Joo Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geon Kook Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyae Young Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung Ho Nam, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Canter, Korea</name>
      <address>
        <city>Ilsan-ro 323, Ilsandoung-gu, Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwan Ho Cho, M.D.</last_name>
      <phone>+82 31 920 1720</phone>
      <email>kwancho@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sung Ho Moon, M.D.</last_name>
      <phone>+82 31 920 1726</phone>
      <email>shmoon@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Sung Ho Moon, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Soo Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heung Tae Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Youn Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tak Yun, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Joo Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2012</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Kwan Ho Cho</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>concurrent chemoradiation in patients with limited disease small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

